Abstract

To address an identified consumer demand for skin care products that can create a natural-looking, lightly suntanned complexion all year round, DSM has been investigating safe means of stimulating skin pigmentation. Its novel pentapeptide Benzoyl Dipeptide-18 D-Phenylalanyl Arginyl D-Tryptophan Diproylamide Mesylate (trading under the name SYN-GLOW™) has been designed and synthesized to act as a melanocortin 1 receptor (MC1R) agonist. Its efficacy has been tested in ex-vivo and in-vivo studies which have demonstrated its potential to initiate and enhance skin pigmentation, with long-lasting results. The findings are presented here.